Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.62 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976623 | 0.91 | OPRM1 (0.52) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| Citric Acid SCHEMBL2965473 | 0.91 | OPRM1 (0.52) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| SCHEMBL2974435 | 0.90 | OPRM1 (0.53) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| SCHEMBL2960492 | 0.89 | OPRM1 (0.51) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| Citric Acid SCHEMBL2968024 | 0.84 | OPRM1 (0.47) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| Citric Acid SCHEMBL2960725 | 0.82 | OPRM1 (0.45) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| SCHEMBL2977285 | 0.81 | OPRM1 (0.60) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| SCHEMBL2970907 | 0.81 | OPRM1 (0.62) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 | |
| SCHEMBL682213 | 0.77 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| Citric Acid SCHEMBL2976393 | 0.74 | OPRM1 (0.50) | OPRM1OGFRL1SMN1; SMN2ALDH1A1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-1778680-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-10-08 | — | — | EP | claimed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1778680-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1778680-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | PKD1, PKD2, NR3C2 | OPRM1 768/4885OGFRL1 1860/4885SMN1; SMN2 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.